Market Closed -
Nasdaq
04:00:00 2024-06-18 pm EDT
5-day change
1st Jan Change
10.62
USD
+1.72%
+1.14%
+134.96%
Presenter SpeechAndrew Ranieri (Analysts)Thank you, everyone, for joining us today. I'm Drew R...
Adma Biologics Insider Sold Shares Worth $2,548,580, According to a Recent SEC Filing
Jun. 17
MT
HC Wainwright Adjusts ADMA Biologics' Price Target to $10 From $7.50, Maintains Buy Rating
May. 10
MT
Cantor Fitzgerald Adjusts ADMA Biologics' Price Target to $10 From $8, Maintains Overweight Rating
May. 10
MT
ADMA Biologics Shares Rise After Company Swings to Q1 Earnings, Lifts 2024 Guidance
May. 10
MT
ADMA Biologics Swings to Q1 Earnings, Revenue Rises; Lifts 2024 Guidance
May. 10
MT
ADMA Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 09
CI
Earnings Flash (ADMA) ADMA BIOLOGICS Posts Q1 Revenue $81.9M, vs. Street Est of $77.3M
May. 09
MT
ADMA Biologics, Inc. Revises Earnings Guidance for the Full Year 2024 and 2025
May. 09
CI
Transcript : ADMA Biologics, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09
ADMA Biologics, Inc. Announces Promotion of Kaitlin Kestenberg as Chief Operating Officer
Apr. 02
CI
HC Wainwright Adjusts ADMA Biologics Price Target to $7.50 From $6, Maintains Buy Rating
Mar. 26
MT
Adma Biologics Insider Sold Shares Worth $2,803,741, According to a Recent SEC Filing
Mar. 20
MT
Adma Biologics, Inc. Announces FDA Approvals of Extended Room Temperature Storage Conditions for Asceniv & Bivigam
Mar. 11
CI
Mizuho Adjusts Price Target on ADMA Biologics to $10 From $9, Maintains Buy Rating
Mar. 01
MT
ADMA Biologics Q4 Net Loss Widens, Revenue Rises; Increases 2024, 2025 Revenue Outlook; Seeks Successor for Chief Financial Officer
Feb. 28
MT
ADMA Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 28
CI
Transcript : ADMA Biologics, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Feb. 28
Earnings Flash (ADMA) ADMA BIOLOGICS Posts Q4 Revenue $73.9M, vs. Street Est of $73M
Feb. 28
MT
ADMA Biologics, Inc. Revises Financial Guidance for the Years 2024 and 2025
Feb. 28
CI
ADMA Biologics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Feb. 28
CI
ADMA Biologics Implements ADMAlytics AI Program to Bolster Production
Feb. 21
MT
ADMA Biologics, Inc Successfully Implements Innovative AI Program, Named ADMAlytics
Feb. 21
CI
Mizuho Securities Raises Price Target on ADMA Biologics to $9 From $7, Maintains Buy Rating
Jan. 22
MT
HC Wainwright Adjusts Price Target on ADMA Biologics to $6 From $5, Maintains Buy Rating
Jan. 09
MT
ADMA Biologics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023, Fiscal Year 2024-2025
Jan. 08
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
More about the company
Last Close Price
10.62
USD
Average target price
11
USD
Spread / Average Target
+3.58%
Consensus
1st Jan change
Capi.
+134.96% 2.42B +2.45% 92.1B -2.63% 37.92B -13.57% 32.97B +75.60% 27.92B -12.73% 16.14B -2.15% 14.1B -11.93% 11.66B +177.66% 10.29B -50.94% 9.99B
Biopharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1